Literature DB >> 11748645

Expression and localization of HGF and met in Wilms' tumours.

Jennifer Alami1, Bryan R G Williams, Herman Yeger.   

Abstract

A number of growth factors and cognate receptors that contribute to normal kidney development have been shown to play roles in the pathogenesis of Wilms' tumours. Expression of both hepatocyte growth factor (HGF) and its tyrosine kinase receptor met has been demonstrated in normal tissues and their neoplastic counterparts, implicating these factors in normal development and tumour progression. HGF and met expression has not been studied in Wilms' tumour. Since HGF and met function in a paracrine fashion by regulating tubulogenesis in normal kidney development, they could be involved in the pathogenesis of Wilms' tumour, in which tubular formation is dysplastic. In the present study, a series of ten homotypic (consisting of blastemal, epithelial, and stromal elements) and ten heterotypic (consisting of triphasic histology and a muscle component) Wilms' tumour cases were examined for expression of HGF and met, using in situ hybridization, immunohistochemistry, and western blot analysis. Relatively high met message and protein expression, compared with normal kidney, were evident in homotypic and heterotypic tumour blastemal, epithelial, and rhabdomyoblastic cells and a 145 kD met polypeptide was found in all tumours, with a few cases also expressing the 170 kD precursor form. No apparent alterations of the met receptor were observed. Similarly, HGF protein was also abundantly expressed in blastemal, epithelial, and rhabdomyoblastic cells of the homotypic and heterotypic Wilms' tumours and a 69 kD HGF polypeptide was demonstrated by western blot analysis. Immunohistochemistry for the Ki-67 proliferation marker indicated that the pattern of Ki-67 expression correlated with the HGF and met pattern of expression in both homotypic and heterotypic tumours. These results reveal, for the first time, significant co-expression of met/HGF in Wilms' tumours, with a correspondingly high proliferative index in the same cell groups. Copyright 2001 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11748645     DOI: 10.1002/path.997

Source DB:  PubMed          Journal:  J Pathol        ISSN: 0022-3417            Impact factor:   7.996


  6 in total

1.  A phase 1 study of the c-Met inhibitor, tivantinib (ARQ197) in children with relapsed or refractory solid tumors: A Children's Oncology Group study phase 1 and pilot consortium trial (ADVL1111).

Authors:  James I Geller; John P Perentesis; Xiaowei Liu; Charles G Minard; Rachel A Kudgus; Joel M Reid; Elizabeth Fox; Susan M Blaney; Brenda J Weigel
Journal:  Pediatr Blood Cancer       Date:  2017-04-27       Impact factor: 3.167

2.  Insulinlike growth factor-I-mediated migration and invasion of human colon carcinoma cells requires activation of c-Met and urokinase plasminogen activator receptor.

Authors:  Todd W Bauer; Fan Fan; Wenbiao Liu; Marjorie Johnson; Nila U Parikh; Graham C Parry; Jennifer Callahan; Andrew P Mazar; Gary E Gallick; Lee M Ellis
Journal:  Ann Surg       Date:  2005-05       Impact factor: 12.969

3.  Differential expression of E-cadherin and beta catenin in primary and metastatic Wilms's tumours.

Authors:  J Alami; B R Williams; H Yeger
Journal:  Mol Pathol       Date:  2003-08

4.  Impact of c-Met expression on angiogenesis in soft tissue sarcomas: correlation to microvessel-density.

Authors:  Cornelius Kuhnen; Thomas Muehlberger; Maria Honsel; Edina Tolnay; Hans Ulrich Steinau; Klaus-Michael Müller
Journal:  J Cancer Res Clin Oncol       Date:  2003-07-09       Impact factor: 4.553

5.  Expression of hepatocyte growth factor and its receptor met in Wilms' tumors and nephrogenic rests reflects their roles in kidney development.

Authors:  Raisa Vuononvirta; Neil J Sebire; Boo Messahel; Nina Perusinghe; Jorge S Reis-Filho; Kathy Pritchard-Jones; Gordan M Vujanic; Chris Jones
Journal:  Clin Cancer Res       Date:  2009-03-24       Impact factor: 12.531

Review 6.  The hepatocyte growth factor/mesenchymal epithelial transition factor axis in high-risk pediatric solid tumors and the anti-tumor activity of targeted therapeutic agents.

Authors:  Megan Grundy; Aru Narendran
Journal:  Front Pediatr       Date:  2022-08-10       Impact factor: 3.569

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.